Sudeep Pharma IPO Listing at 23.10% Premium at ₹730 Per Share
Fri Nov 28 2025
Sudeep Pharma IPO listing: The Sudeep Pharma IPO was subscribed 93.71 times at the time of its closing. In this subscription, qualified institutional buyers (QIBs) received 213.08 times, and non-institutional investors (NIIs) received 116.72 times. The retail quota of the issue was subscribed to 35.00%. Before delving deeper into the topic, go through the details of the Sudeep Pharma IPO.
Sudeep Pharma IPO
It is a book-building issue of 895.00 crore shares, comprising a fresh issue of 0.16 crore shares and an offer-for-sale of 1.35 crore shares. The IPO is expected to be listed on the BSE and NSE, with a tentative listing date of 28th November 2025. The Sudeep Pharma IPO is scheduled to take place from 21st November 2025 to 25th November 2025. The face value of Sudeep Pharma IPO shares is ₹1 per share, and the IPO price is set at ₹563.00 to ₹593.00 per share.
| IPO Open Date | 21st November 2025 |
| IPO Close Date | 25th November 2025 |
| IPO Allotment Date | 26th November 2025 |
| Refund Initiation | 27th November 2025 |
| Face Value | ₹1 per share |
| Price Band | ₹563 to ₹593 per share |
| Lot Size | 25 Shares |
| Issue Size | 1,50,92,750 shares(aggregating up to ₹895.00 Cr) |
| Fresh Issue | 16,02,024 shares(aggregating up to ₹95.00 Cr) |
| Offer for sale | 1,34,90,726 shares of ₹1(aggregating up to ₹800.00 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE and NSE |
| Listing Date | 28th November 2025 |
Sudeep Pharma IPO Listing
On the NSE platforms, Sudeep Pharma shares are listed at ₹730 per share, reflecting a 23.10% premium over the issue price of ₹593 per share.
About the Sudeep Pharma IPO Listing
Sudeep Pharma was established in 1989 and is a manufacturer of pharmaceutical excipients, food-grade minerals, and speciality nutrition ingredients serving over 100 countries. The company operates six manufacturing facilities with a combined production capacity of 50,000 MT, specializing in minerals such as calcium, iron, magnesium, zinc, potassium, and sodium. The company supplies over 200 products to a diverse customer base across the pharmaceutical, food, and nutrition sectors. The company has strong R&D capabilities with in-house labs and pilot-scale facilities focused on mineral salts and excipients.
Market leadership with a diversified product portfolio in a high-barrier industry
Distinguished global customer base with long-standing relationships with key customers
Well-equipped and regulatory-compliant Manufacturing Facilities
Intense research and development capabilities
Sudeep Pharma Limited Financials
The company’s financial analysis is essential before applying for Sudeep Pharma Limited’s IPO. Refer to the table to learn about Sudeep Pharma Limited’s financial information.
| Year Ended | 30th June 2025 | 31st March 2025 (in cr.) | 31st March 2024 (in cr.) | 31st March 2023 (in cr.) |
| Assets | 922.26 | 717.17 | 513.87 | 420.11 |
| Revenue | 130.08 | 511.33 | 465.38 | 438.26 |
| Profit After Tax | 31.27 | 138.69 | 133.15 | 62.32 |
| EBITDA | 48.57 | 199.28 | 187.76 | 98.64 |
| Net Worth | 688.32 | 497.53 | 359.07 | 226.29 |
| Reserve and Surplus | 668.52 | 481.11 | 354.59 | 221.88 |
| Total Borrowing | 135.97 | 135.25 | 75.03 | 82.26 |
Explanation
Sudeep Pharma Limited’s revenue increased by 10% from ₹465.38 crore in March 2024 to ₹511.33 crore in March 2025. Moreover, the company’s PAT increased by 4% from ₹133.15 crores to ₹138.69 crores. Investors can analyse other relevant factors and make a decision accordingly.
Recent Articles
Best Penny Stocks for Long Term in India | Penny Stocks in 2025
Berger Paints Q1 Results FY26: Q1 PAT Narrows 11.01% to ₹314.63 Crore; Revenue Surged 3.55% YoY
Tega Industries Q1 Results FY26: Q1 PAT Falls 3.83% to ₹35.34 Crore; Revenue Jumps 4.74% YoY
Alembic Pharmaceuticals Q1 Results FY26: Q1 PAT Soars 14.60% to ₹154.38 Crore; Revenue Up 9.54% YoY
